Association after linkage analysis indicates that homozygosity for the 46C→ T polymorphism in the Fl2 gene is a genetic risk factor for venous thrombosis

Thrombosis and Haemostasis

Volumn 91, Issue 5, 2004, Pages 899-904

  Tirado, Isabel ^a   Soria, José Manuel ^a   Mateo, José ^a   Oliver, Arthur ^a   Souto, Juan Carlos ^a   Santamaria, Amparo ^a   Felices, Rosa ^a   Borrell, Montserrat ^a   Fontcuberta, Jordi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Complex disease; Genetics; Risk factors; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 12; CYTOSINE; DNA; THYMIDINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; IDIOPATHIC DISEASE; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPAIN; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 2442465593     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-10-0620     Document Type: Article

References (39)

1. Coon WW, Park WW, Keller JB. Venous thromboemolism and other venous disease in the Tecumseh Community Health Study. Circulation 1973; 48: 839-46.
2. Nordstrom M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deepvein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
3. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
4. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
5. Soria JM, Almasy L, Souto JC, et al. Linkage analysis demonstrated that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000; 95: 2780-5.
6. Soria JM, Almasy L, Souto JC, et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 2002; 70: 567-74.
7. Dahlback B. Successful hunt for quantitative trait locus in thrombophilia. Arterioscler Thromb Vasc Biol 2003; 23: 376-7.
8. Souto JC, Almasy L, Burrell M, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-51.
9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant reponse to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
10. Hyland K, Bottiglieri T. Measurement of total plasma and cerebrospinal homocysteine by fluorescence following high-performance liquid chromatography and precolumn with opthaldialdehyde. J Chromatography 1992; 79: 55-62.
11. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1987; 40: 143-51.
12. Gharavi AE, Harris EN, Asherson RA, et al. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1-6.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16: 1215.
14. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
15. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
16. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
17. Souto JC, Coll I, Llobet D, et al. The Prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-9.
18. Rowen L, Mahairas G, Hood L. Sequencing the human genome. Science 1997; 278: 605-7.
19. Gelbert LM, Gregg RE. Will genetics really revolutionize the drug discovery process? Curr Opin Biotechnol 1997; 8: 669-74.
20. Endler G, Exner M, Mannhalter C, et al. A common C→T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res 200t; 101: 255-60.
21. Zito F, Drummond F, Bujac SR, et al. Epidemiological and genetics associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
22. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet t995; 346: 1133-4.
23. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706.
24. van der Meer FJM, Koster T, Vanderçnbroucke JP, et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-5.
25. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
26. Rosendaal, FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
27. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Am J Hum Genet 2000; 67: 1452-9.
28. Ishii K, Oguchi S, Murata M, et al. Activated factor XII levels are dependent on factor XII 46 C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects. Blood Coagul Fibrinolysis 2000; 11: 277-84.
29. Kholer HP, Carter AM, Stickland MH, et al. Levels of activated FXII in survivors of myocardial infarction-association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-8.
30. Oguchi S, Ito D, Murata M, et al. Genotype distribution of the 46 C/T polymorphism of coagulation factor XII in the japanese population: absence of its association with ischemic cerebrovascular disease. Throm Haemost 2000; 83: 178-9.
31. Kohler HP, Fusters TS, Granbt PJ. FXII (46C→T) polymorphism and in vivo generation of FXII activity- gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 81: 745-7.
32. Gambaro G, Anglani F, D'Angelo A. Association studies of genetic polymophisms and complex disease. Lancet 2000; 355: 308-11.
33. Almasy L, MacCluer JW. Association studies of vascular phenotypes: how and why? Arterioscler Thromb Vasc Biol 2002; 22: 1055-7.
34. Editorial. Freely associating. Nature Genetics 1999; 22: 1-2.
35. Cooper DN, Nussabaum RL, Krawczak M. Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 2002; 110: 207-8.
36. Sterne JA, Smith D. Sifting the evidence-what's wrong with significance tests? BMJ 2001; 322: 226-31.
37. Foncea N, Gomez Beldarrain M, Ruiz Ojeda J, et al. Ischemic stroke in a patient with factor XII (Hageman) deficiency. Neurologia 2001; 16: 227-8.
38. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic of activated FXII. Eur J Bichem 1999; 263: 904-11.
39. Miller GJ, Esnouf MP, Burgess AI, et al. Risk of coronary heart disease and activation of factor XII in middle-aged men. Aterioscler Thromb Vasc Biol 1997; 17: 2103-6.